Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia
Issued Date
2023-04-01
Resource Type
ISSN
15560864
eISSN
15561380
Scopus ID
2-s2.0-85143855499
Pubmed ID
36379356
Journal Title
Journal of Thoracic Oncology
Volume
18
Issue
4
Start Page
436
End Page
446
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Thoracic Oncology Vol.18 No.4 (2023) , 436-446
Suggested Citation
Mitsudomi T., Tan D., Yang J.C.H., Ahn M.J., Batra U., Cho B.C., Cornelio G., Lim T., Mok T., Prabhash K., Reungwetwattana T., Ren S.X., Singh N., Toyooka S., Wu Y.L., Yang P.C., Yatabe Y. Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia. Journal of Thoracic Oncology Vol.18 No.4 (2023) , 436-446. 446. doi:10.1016/j.jtho.2022.10.021 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/82349
Title
Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia
Author's Affiliation
Okayama University Hospital
Tongji University School of Medicine
Yonsei Cancer Hospital
National Taiwan University Hospital
University of the Philippines Manila
Rajiv Gandhi Cancer Institute and Research Centre
Guangdong General Hospital
National Cancer Centre, Singapore
Kindai University School of Medicine
Samsung Medical Center, Sungkyunkwan University
National Cancer Center Hospital
Singapore General Hospital
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Advanced Centre for Treatment, Research & Education in Cancer
Chinese University of Hong Kong
Postgraduate Institute of Medical Education & Research, Chandigarh
Tongji University School of Medicine
Yonsei Cancer Hospital
National Taiwan University Hospital
University of the Philippines Manila
Rajiv Gandhi Cancer Institute and Research Centre
Guangdong General Hospital
National Cancer Centre, Singapore
Kindai University School of Medicine
Samsung Medical Center, Sungkyunkwan University
National Cancer Center Hospital
Singapore General Hospital
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Advanced Centre for Treatment, Research & Education in Cancer
Chinese University of Hong Kong
Postgraduate Institute of Medical Education & Research, Chandigarh
Other Contributor(s)
Abstract
Introduction: Most published guidelines for genomic biomarker testing in NSCLC reflect the disease epidemiology and treatments readily available in Europe and North America. Nevertheless, 60% of annual global NSCLC cases occur in Asia, where patient characteristics, tumor molecular profiles, and treatments vary greatly from the Western world. For example, mutations in the EGFR occur at a higher prevalence in Asia than in other world regions. Although medical associations such as the International Association for the Study of Lung Cancer, European Society for Medical Oncology, and American Society of Clinical Oncology have described principles for tumor genomic biomarker testing in NSCLC, there is a need for recommendations specific for Asia. Methods: This report provides consensus recommendations for NSCLC biomarker testing from Asian lung cancer experts for clinicians working in Asia to improve patient care. Biomarker testing approaches for actionable genetic alterations in EGFR, ALK, ROS1, and others are discussed. Results: These recommendations are divided into nonmetastatic and metastatic forms of adenocarcinoma and squamous cell carcinoma. Owing to the higher prevalence of EGFR mutations in Asia, the experts emphasized the need for EGFR testing to include not just common mutations (exon 19 deletions and L858R substitutions) but also other uncommon EGFR mutations. In addition to the assessment of biomarkers in the tumor tissue, the role of assessing tumor biomarkers by liquid biopsy is discussed. Conclusion: This consensus provides practical recommendations for biomarker testing in nonmetastatic and metastatic Asian NSCLC patients.